Abstract
Certain anti-cancer prodrugs are subject to cytochrome P450 (CYP)-mediated metabolism and become more active. Because CYP activity may be regulated by phosphorylation via adenylyl cyclase/protein kinase A, selective adenylyl cyclase subtype activators may be utilized in future chemotherapy to regulate CYP activity as a switch in a tumor tissue-specific manner.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenylyl Cyclases / metabolism
-
Animals
-
Antineoplastic Agents / metabolism*
-
Antineoplastic Agents / therapeutic use
-
Cyclic AMP / metabolism
-
Cyclic AMP-Dependent Protein Kinases / metabolism
-
Cytochrome P-450 Enzyme System / metabolism*
-
Enzyme Activators / pharmacology
-
Humans
-
Neoplasms / drug therapy
-
Phosphorylation
-
Prodrugs / metabolism*
-
Prodrugs / therapeutic use
Substances
-
Antineoplastic Agents
-
Enzyme Activators
-
Prodrugs
-
Cytochrome P-450 Enzyme System
-
Cyclic AMP
-
Cyclic AMP-Dependent Protein Kinases
-
Adenylyl Cyclases